This study was conducted to test the hypothesis that the margin of safe fluoride exposure is narrowed in rats that are physiologically compromised by renal dysfunction. The study objective was to determine whether increases in fluoride retention and tissue fluoride levels in rats with surgically induced renal insufficiency result in toxic fluoride effects not ordinarily observed in healthy animals. Uremic and sham-operated control rats received 0 µg/ml, 5 (0.26 mmol/l), 15 (0.79), or 50 µg/ml (2.63 mmol/l) of fluoride in their drinking water for 3 or 6 months. Fluoride retention was monitored, and, following euthanasia, tissue fluoride and biochemical markers of tissue function were analyzed. Selected tissues were saved for histology, and bone marrow cells were harvested for determining the frequency of sister chromatid exchange, a marker of genetic damage. In spite of significantly higher levels of fluoride in the tissues of the animals with renal insufficiency, there were no clinically adverse, fluoride-induced, extraskeletal physiological, biochemical, or genetic effects of chronic exposure to common levels of fluoride in these rats.

National Research Council: Health Effects of Ingested Fluoride. Washington, National Academy Press, 1993.
Smith GE: A surfeit of fluoride? Sci Prog 1985;69:429–442.
Ekstrand J, Spak CJ, Vogel G: Pharmacokinetics of fluoride in man and its clinical relevance. J Dent Res 1990;69:550–555.
Whitford GM (ed): The Metabolism and Toxicity of Fluoride. Monogr Oral Sci. Basel, Karger, 1996, vol 16, chap IV.
Franscino JA, Freed BR, Woodard HQ: Fluoride-18 metabolism in the acutely uremic rat. Health Phys 1975;29:279–283.
Siddiqui JY, Simpson W, Ellis HA, Kerr DNS: Serum fluoride in chronic renal failure. Proc Eur Dial Transplant Assoc 1970;7:110–117.
Schiffl HH, Binswanger U: Human urinary fluoride excretion as influenced by renal functional impairment. Nephron 1980;26:69–72.
Spencer H, Kramer L, Gatza C, Norris C, Wiatrowski E, Gandhi VC: Fluoride metabolism in patients with chronic renal failure. Arch Intern Med 1980;140:1331–1335.
Hanhijarvi H, Penttila I: The relationship between human ionic plasma fluoride and serum creatinine concentration in cases of renal and cardiac insufficiency in a fluoridated community. Proc Finn Dent Soc 1981;77:330–333.
Parsons V, Choudhury AA, Wass JAH, Vernon A: Renal excretion of fluoride in renal failure and after renal transplantation. Br Med J 1975;1:128–130.
Waterhouse C, Taves D, Munzer A: Serum inorganic fluoride: Changes related to previous fluoride intake, renal function and bone resorption. Clin Sci 1980;58:145–152.
Hanhijarvi H: The effect of renal impairment on fluoride retention of patients hospitalized in a low-fluoride community. Proc Finn Dent Soc 1982;78:13–19.
Ormond D, Miller T: Experimental uremia. Nephron 1980;26:249–254.
Turner CH, Owan I, Brizendine EJ, Zhang W, Wilson ME, Dunipace AJ: High fluoride intakes cause osteomalacia and diminished bone strength in rats with renal deficiency. Bone 1996;19:595–601.
Perry P, Thomson EJ: The methodology of sister chromatid exchanges; in Kilby BJ, Legator M, Nichols W, Ramel C (eds): Handbook of Mutagenicity Test Procedures, ed 2. Amsterdam, Elsevier, 1984.
Taves DR: Separation of fluoride by rapid diffusion using hexamethyldisiloxane. Talanta 1968;15:969–974.
Dunipace AJ, Brizendine EJ, Zhang W, Wilson ME, Miller L, Katz BP, Warrick J, Stookey, GK: Effect of aging on animal response to chronic fluoride exposure. J Dent Res 1995;74:358–368.
Goto K, Maeda S, Kano Y, Sugiyama T: Factors involved in differential Giemsa-staining of sister chromatids. Chromosoma 1978;66:351–359.
Fejerskov O, Kragstrup J, Rishards A: Fluorosis of teeth and bones; in Ekstrand J, Fejerskov O, Silverstone LM (eds): Fluoride in Dentistry. Copenhagen, Munksgaard, 1988.
Whitford GM, Pashley DH, Stringer GI: Fluoride renal clearance: A pH-dependent event. Amer J Physiol 1976;230:527–532.
Jackson R, Kelly S, Noblitt TW, Zhang W, Dunipace A, Li Y, Stookey G, Katz B, Brizendine E, Farley S, Baylink D: The effect of fluoride therapy on blood chemistry parameters in osteoporotic females. Bone Miner 1994;27:13–23.
Latt SA: Sister chromatid exchanges, indices of human chromosome damage and repair: Detection by fluorescence and induction by mitomycin C. Proc Natl Acad Sci USA 1974;71:3162–3166.
Perry P, Evans HJ: Cytological detection of mutagen-carcinogen exposure by sister chromatid exchange. Nature 1975;258:121–125.
Posen GA, Marier JR, Jaworski ZF: Renal osteodystrophy in patients on long-term hemodialysis with fluoridated water. Fluoride 1971;4:114–128.
Cordy PE, Gagnon R, Taves DR, Kaye M: Bone disease in hemodialysis patients with particular reference to the effect of fluoride. Trans Am Soc Artif Intern Organs 1974;20:197–202.
Mehls O, Ritz E, Gille G, Wingen AM: Osteodystrophy in experimental uremia; in Gretz N, Strauch M (eds): Animal Models in Chronic Renal Failure. Contrib Nephrol. Basel, Karger, 1988, vol 60, pp 207–213.
Richards A: Nature and mechanisms of dental fluorosis in animals. J Dent Res 1990; 69:701–705.
Taves DR, Freedman RB, Kamm DB, Ramos SP, Scribner BH: Hemodialysis with fluoridated dialysate. Trans Am Soc Artif Intern Organs 1968;14:412–414.
Bello VAO, Gitelman HJ: High fluoride exposure in hemodialysis patients. Am J Kidney Dis 1990;15:320–324.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.